After a year defined more by cautious observation than by headline-grabbing transactions, the undercurrents of strategic realignment and technological disruption are now set to propel healthcare M&A into a period of dramatic resurgence. The market has spent months recalibrating expectations and
A New Era in HER2-Positive Breast Cancer Treatment The landscape of breast cancer treatment has been dramatically reshaped with the U.S. Food and Drug Administration (FDA) granting approval for Enhertu as a first-line therapy for adults with unresectable or metastatic HER2-positive breast cancer.
With over two decades of experience at the forefront of medical device manufacturing and innovation, Faisal Zain has a unique vantage point on the complex dance between technology and regulation. His work gives him a ground-level view of how decisions made within the halls of the Food and Drug
A Call for a 21st-Century Framework: Why AI in Healthcare Demands a New Regulatory Playbook In a pivotal moment for digital health, the American Hospital Association (AHA) has formally called on the U.S. Food and Drug Administration (FDA) to overhaul its regulatory approach to artificial
As nations around the globe grapple with the monumental task of reshaping their healthcare systems, a critical question emerges from the frontlines of patient care: are the architects of reform listening to the very professionals tasked with implementing their ambitious plans? Sweeping policy
Walking the sprawling exhibition halls of the Radiological Society of North America’s annual meeting reveals an astonishing reality about the state of modern medicine, where a company once known exclusively for powering video games has become the silent, indispensable engine of healthcare i
